Pollok, Karen E.

TGF-β1–induced expression of human Mdm2 correlates with late-stage metastatic breast cancer

Araki, S., Eitel, J. A., Batuello, C. N., Bijangi-Vishehsaraei, K., Xie, X.-J., Danielpour, D., Pollok, K. E., Boothman, D. A., & Mayo, L. D. (2010) · Journal of Clinical Investigation

TGF-β signaling in diseasesCancer-related Molecular Pathways

Cited by 133

Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist

Wang, H., Cai, S., Bailey, B. J., Reza Saadatzadeh, M., Ding, J., Tonsing-Carter, E., Georgiadis, T. M., Zachary Gunter, T., Long, E. C., Minto, R. E., et al. (2017) · Journal of Neurosurgery

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 49

Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model

Tonsing-Carter, E., Bailey, B. J., Saadatzadeh, M. R., Ding, J., Wang, H., Sinn, A. L., Peterman, K. M., Spragins, T. K., Silver, J. M., Sprouse, A. A., et al. (2015) · Molecular Cancer Therapeutics

Cancer-related Molecular PathwaysBreast Cancer Treatment Studies

Cited by 42

Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity

Cai, S., Wang, H., Bailey, B., Ernstberger, A., Juliar, B. E., Sinn, A. L., Chan, R. J., Jones, D. R., Mayo, L. D., Baluyut, A. R., et al. (2011) · Clinical Cancer Research

Hematopoietic Stem Cell TransplantationImmunotoxicology and immune responses

Cited by 32